LEQEMBI Treatment for Alzheimer's Disease
A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
- Age
- 19 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 3,000 (estimated)
- Sponsor
- Eisai Korea Inc. · Industry
This trial is looking for people with Alzheimer's disease who are already set to receive a treatment called LEQEMBI. Participants will share their experiences to help evaluate the treatment's safety in real-life settings.
You may be able to join if
- I am enrolled in JOY-ALZ before deciding to treat with LEQEMBI
- The decision to treat me with LEQEMBI has already been made
- I have given written permission for my medical information to be shared
You may not be able to join if
- I am currently participating in another clinical study
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe primary purpose of this study is to evaluate safety of LEQEMBI in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in patients treated with LEQEMBI.
Loading trial locations…
Eisai Korea Inc. Medical department Serena SoYoun Kwon
+82-2-3451-5533
CONTACT